Editing Hepatitis (section)

=== Non-alcoholic steatohepatitis ===
Non-alcoholic steatohepatitis (NASH) is projected to become the top reason for [[liver transplantation]] in the United States by 2020, supplanting chronic liver disease due to hepatitis C.<ref name="From NAFLD to NASH">{{Cite journal|last1=Wree|first1=Alexander|last2=Broderick|first2=Lori|last3=Canbay|first3=Ali|last4=Hoffman|first4=Hal M.|last5=Feldstein|first5=Ariel E.|date=2013-11-01|title=From NAFLD to NASH to cirrhosis-new insights into disease mechanisms|journal=Nature Reviews. Gastroenterology & Hepatology|volume=10|issue=11|pages=627–636|doi=10.1038/nrgastro.2013.149|issn=1759-5053|pmid=23958599|s2cid=6899033}}</ref>  About 20–45% of the U.S. population have NAFLD and 6% have NASH.<ref name="Friedman 55e" /><ref name="Harrison's Principles chapter 364 (Nonalcoholic)" /> The estimated prevalence of NASH in the world is 3–5%.<ref name="Weiß, Rau, Geier">{{Cite journal|last1=Weiß|first1=Johannes|last2=Rau|first2=Monika|last3=Geier|first3=Andreas|date=2014-06-27|title=Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment|journal=Deutsches Ärzteblatt International|volume=111|issue=26|pages=447–452|doi=10.3238/arztebl.2014.0447|issn=1866-0452|pmc=4101528|pmid=25019921}}</ref>  Of NASH patients who develop [[cirrhosis]], about 2% per year will likely progress to [[hepatocellular carcinoma]].<ref name="Weiß, Rau, Geier" />   Worldwide, the estimated prevalence of hepatocellular carcinoma related to NAFLD is 15–30%.<ref name="NAFLD, NASH and liver cancer">{{Cite journal|last1=Michelotti|first1=Gregory A.|last2=Machado|first2=Mariana V.|last3=Diehl|first3=Anna Mae|date=2013-11-01|title=NAFLD, NASH and liver cancer|journal=Nature Reviews. Gastroenterology & Hepatology|volume=10|issue=11|pages=656–665|doi=10.1038/nrgastro.2013.183|issn=1759-5053|pmid=24080776|s2cid=22315274}}</ref> NASH is thought to be the primary cause of cirrhosis in approximately 25% of patients in the United States, representing 1–2% of the general population.<ref name="NAFLD, NASH and liver cancer" />